Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.

Angelopoulos N, Zianni D, Livadas S, Androulakis I, Fousteris E, Paparodis R, Petkova V, Florakis D, Mouslech Z, Rizoulis A, Perogamvros I, Tzoulis P, Askitis D, Argyrakopoulou G, Lambadiari V

Diabetes, obesity & metabolism27 Apr 2026Cited by 1 (Europe PMC)

PMID42037110DOI10.1111/dom.70810PepBankPUB-42037110

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity in routine care, 208 of 260 patients (80%) completed 6 months of tirzepatide.
In plain wordsIn adults with obesity, 80% of patients (208 of 260) completed 6 months of tirzepatide in routine care.
Peptide
Tirzepatide
Outcome
Not applicableTreatment persistence at 6 months
Study
n = 260
Outcome group
Adverse events · Whole body
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Measurements
completed 6 months
208 patients
of 260 initiators
completed 6 months
80%
of 260 initiators
Source sentences
Summary
A total of 260 patients initiated tirzepatide, of whom 208 (80%) completed 6 months of therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711009
02HumanObservational studySafety outcome
In adults with obesity in routine care, 20% of patients discontinued tirzepatide, most commonly during the titration phase, mainly for goal achievement, cost, non-response or adverse events.
In plain wordsIn adults with obesity, 20% stopped tirzepatide, most often early in dose increase, for reasons such as reaching goal, cost, no response or side effects.
Peptide
Tirzepatide
Outcome
Not applicableTreatment discontinuation
Study
n = 260
Outcome group
Adverse events · Whole body
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Measurements
discontinuation
20%
tirzepatide
Source sentences
Summary
Treatment discontinuation occurred in 20% of patients, most commonly during the titration phase, primarily due to goal achievement, cost, non-response or adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711010
03HumanObservational studySafety outcome
In adults with obesity in routine care, gastrointestinal adverse events were the most frequently reported with tirzepatide but rarely led to treatment discontinuation.
In plain wordsIn adults with obesity on tirzepatide, gut-related side effects were the most common but rarely made people stop treatment.
Peptide
Tirzepatide
Outcome
Not applicableGastrointestinal adverse events
Study
n = 260
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events were the most frequently reported but rarely led to treatment discontinuation.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711011
04HumanObservational studyEfficacy outcome
In adults with obesity in routine care, 94.2% achieved weight loss of 5% or more after 6 months of tirzepatide.
In plain wordsIn adults with obesity, 94.2% lost at least 5% of their weight after 6 months of tirzepatide in routine care.
Peptide
Tirzepatide
Outcome
Not applicableWeight loss of 5% or more
Study
n = 208
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Measurements
proportion with weight loss 5% or more
94.2%
6 months
Source sentences
Summary
94.2% achieving ≥ 5% weight loss
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711001
05HumanObservational studyEfficacy outcome
In adults with obesity in routine care, 77.9% achieved weight loss of 10% or more after 6 months of tirzepatide.
In plain wordsIn adults with obesity, 77.9% lost at least 10% of their weight after 6 months of tirzepatide in routine care.
Peptide
Tirzepatide
Outcome
Not applicableWeight loss of 10% or more
Study
n = 208
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Measurements
proportion with weight loss 10% or more
77.9%
6 months
Source sentences
Summary
77.9% ≥ 10%
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711002
06HumanObservational studyEfficacy outcome
In adults with obesity in routine care, 47.1% achieved weight loss of 15% or more after 6 months of tirzepatide.
In plain wordsIn adults with obesity, 47.1% lost at least 15% of their weight after 6 months of tirzepatide in routine care.
Peptide
Tirzepatide
Outcome
Not applicableWeight loss of 15% or more
Study
n = 208
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Measurements
proportion with weight loss 15% or more
47.1%
6 months
Source sentences
Summary
47.1% ≥ 15%
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711003
07HumanObservational studyEfficacy outcome
In adults with obesity in routine care, approximately 20% achieved weight loss of 20% or more after 6 months of tirzepatide.
In plain wordsIn adults with obesity, about 20% lost at least 20% of their weight after 6 months of tirzepatide in routine care.
Peptide
Tirzepatide
Outcome
Not applicableWeight loss of 20% or more
Study
n = 208
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Measurements
proportion with weight loss 20% or more
≈ 20%
6 months
Source sentences
Summary
approximately 20% ≥ 20%
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711004
08HumanObservational studyEfficacy outcome
In adults with obesity in routine care, body weight decreased significantly from baseline after 6 months of tirzepatide, with a large effect size.
In plain wordsIn adults with obesity, body weight fell clearly after 6 months of tirzepatide in routine care.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change from baseline
Study
n = 208
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Source sentences
Summary
Body weight and BMI decreased significantly from baseline (p < 0.001), with a large effect size.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711005
09HumanObservational studyEfficacy outcome
In adults with obesity in routine care, BMI decreased significantly from baseline after 6 months of tirzepatide, with a large effect size.
In plain wordsIn adults with obesity, BMI fell clearly after 6 months of tirzepatide in routine care.
Peptide
Tirzepatide
Outcome
DecreaseBody mass index change from baseline
Study
n = 208
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Source sentences
Summary
Body weight and BMI decreased significantly from baseline (p < 0.001), with a large effect size.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711006
10HumanObservational studyEfficacy outcome
In adults with obesity in routine care, women achieved a greater percentage weight loss than men on tirzepatide (p = 0.042).
In plain wordsIn adults with obesity on tirzepatide in routine care, women lost a larger share of their weight than men.
Peptide
Tirzepatide
Outcome
Not applicableWeight loss by sex
Study
n = 208
Comparator
Men
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Source sentences
Summary
Weight-loss magnitude was independent of baseline BMI and obesity class, while women achieved a greater percentage weight loss than men (p = 0.042).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711007
11HumanObservational studyEfficacy outcome
In adults with obesity in routine care, weight-loss magnitude with tirzepatide was independent of baseline BMI and obesity class.
In plain wordsIn adults with obesity on tirzepatide in routine care, the size of weight loss did not depend on starting BMI or obesity class.
Peptide
Tirzepatide
Outcome
No significant changeWeight loss by baseline BMI and obesity class
Study
n = 208
Outcome group
Body weight · Metabolic and weight
Studied dose
low- to moderate-dose · 6 monthsAs given in this study (human).
Source sentences
Summary
Weight-loss magnitude was independent of baseline BMI and obesity class
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre retrospective observational study evaluated adults with obesity who initiated tirzepatide in routine clinical practice across 15 endocrinology clinics in Greece between December 2024 and May 2025.
Summary · context
Patients with available baseline and 6-month follow-up (±2 weeks) data were included.
Report a problemFND-4203711008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.

Summary

Results from this study11

Version history

Subjects

Publication types

MeSH terms

Keywords